

Additional Resources

World Health Organization

- Program guidelines and recommendations:
http://www.who.int/substance_abuse/publications/management_opioid_overdose/en/

Toward the Heart Program

- BC program *Toward the Heart*, with copies of training manuals, videos, and sample kits:
<http://towardtheheart.com/naloxone/>
- Sample overdose prevention pamphlet:
http://towardtheheart.com/assets/uploads/files/OD_Survival_Guide_Tips_to_Save_a_Life_2012.08.29_upright_for_website.pdf
- Resources for establishing cooperative relationships with law enforcement and first responders:
<http://towardtheheart.com/naloxone/law-enforcement/>
- Possible training video includes naloxone procedure and tips to avoid overdose:
<http://www.youtube.com/watch?v=U1frPJoWtkw>
- Peer-reviewed publication of program outcomes:
<http://www.cmajopen.ca/content/2/3/E153.full>

Canadian Aids Treatment Information Exchange (CATIE)

- Best Practice Recommendations for Canadian Harm Reduction Programs that Provide Service to People Who Use Drugs and are at Risk for HIV, HCV, and Other Harms, Part 1, Chapter 11 - Opioid overdose prevention: education and naloxone distribution:
<http://www.catie.ca/en/programming/best-practices-harm-reduction>
- Description/case study of *Street Works*, the Edmonton, AB naloxone program:
<http://www.catie.ca/en/pc/program/overdose-prevention-project>
- Sample funding application:
<http://www.catie.ca/sites/default/files/Drug%20Education%20and%20Overdose%20Prevention.pdf>

Naloxone Info

- Annotated bibliography, case studies, fact sheets, advice on starting a program, etc.:
<http://www.naloxoneinfo.org/>

European Monitoring Centre for Drugs and Drug Addiction

- Preventing overdose deaths overview:
<http://www.emcdda.europa.eu/topics/pods/preventing-overdose-deaths>
- Best practice portal: Harm reduction interventions for opioid injectors:
<http://www.emcdda.europa.eu/best-practice/harm-reduction/opioid-injectors>
- Systematic review of the effectiveness of take-home naloxone:
<http://www.emcdda.europa.eu/publications/emcdda-papers/naloxone-effectiveness>

Canadian Centre on Substance Abuse

- Prescription Opioids in Canada: Overview:
<http://ccsa.ca/Resource%20Library/CCSA-Canadian-Drug-Summary-Prescription-Opioids-2013-en.pdf>
- Misuse of Opioids in Canadian Communities:
<http://ccsa.ca/Resource%20Library/ccsa-CCENDU-Opioid-Bulletin-2013-en.pdf#search=naloxone>
- First Do No Harm: Responding to Canada's Prescription Drug Crisis:
<http://www.ccsa.ca/resource%20library/canada-strategy-prescription-drug-misuse-report-en.pdf>

Hungarian Civil Liberties Union (HCLU) / Drug Reporter

- Animated training video:
http://drogriporter.hu/en/Bunny_and_wolf-fight_overdose_animated_guide

Canadian Drug Policy Coalition

- Opioid Overdose Prevention & Response in Canada: http://drugpolicy.ca/wp-content/uploads/2014/05/CDPC_Overdose-Prevention-Policy.pdf

Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain.

Includes:

- Extensive guidelines for opioid prescribers: <http://nationalpaincentre.mcmaster.ca/opioid/>
- Easy to use tools for physicians and patients to assess and manage opioid overdose risk: <http://nationalpaincentre.mcmaster.ca/tools.htm>

References

- Albert, S., Brason, F.W. 2nd, Sanford, C.K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in rural North Carolina. *Pain Medicine*, 12(Suppl 2), S77–S85.
- Alexander, G.C., Kruszewski, S.P., & Webster, D.W. (2012). Rethinking opioid prescribing to protect patient safety and public health. *JAMA*, 308, 1865–1866.
- Ashton, R. (2006). Intranasal naloxone in suspected opioid overdose. *Emergency Medicine Journal*, 23, 221-223.
- Association pour la Défense des Droits et l'Inclusion des personnes qui Consomment des drogues du Québec [ADDICQ]. (2012). *Guideline for the inclusion of drug users*. Montréal (Québec): ADDICQ. Retrieved from: <http://linjecteur.ca/addicq/PDF/Guideline%20for%20the%20inclusion%20of%20drug%20users-web.pdf>
- Auriacombe, M., Franques, P., & Tignol, J. (2001). Deaths attributable to buprenorphine versus methadone in France. *JAMA*, 285, 45.
- Baca, C.T. & Grant, K.J. (2005). Take-home naloxone to reduce heroin death. *Addiction*, 100, 1823–1831.
- Ballantyne, J.C. & Shin, N.S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. *Clinical Journal of Pain*, 24, 469-478.
- Bell, J.R., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P. (2009). Comparing overdose mortality associated with methadone and buprenorphine treatment. *Drug and alcohol dependence*, 104(1), 73-77.
- Bennett, A.S., Bell, A., Tomedi, L., Hulse, E.G., & Kral, A.H. (2011). Characteristics of an overdose prevention and response and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. *Journal of Urban Health*, 88, 1020–1030.
- Branswell, H. (2015). Naloxone's prescription-only status to get Health Canada review. CBC. July 24. Retrieved from: <http://www.cbc.ca/news/health/naloxone-s-prescription-only-status-to-get-health-canada-review-1.3166867>
- Broadhead, R.S., Heckathorn, D.D., Weakliem, D.L., Anthony, D.L., Madray, H., Mills, R.J., & Hughes, J. (1998). Harnessing peer networks as an instrument for AIDS prevention: Results from a peer-driven intervention. *Public Health Reports*, 113, 42–57.
- Brugal, M., Barrio, G., De, L.F., Regidor, E., Royuela, L., & Suelves, J.M. (2002). Factors associated with non-fatal heroin overdose: Assessing the effect of frequency and route of heroin administration. *Addiction*, 97, 319–327.

Physicians for Responsible Opioid Prescribing

- Cautious, Evidence-Based Opioid Prescribing Guidelines: Additional information on safer prescribing practices: http://www.supportprop.org/educational/PROP_OpioidPrescribing.pdf

Overdose Prevention Programming:
Education and Naloxone Distribution

- Brugal, M., Domingo-Salvany, A., Puig, R., Barrio, G., García de Olalla, P., & de la Fuente, L. (2005). Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. *Addiction, 100*, 981–989.
- Campana, M. (2000). *Overdose mortality and naloxone distribution in Italy*. Paper presented at the “Preventing Heroin Overdose: Pragmatic Approaches” conference. Seattle, Washington, January 13-14, 2000.
- Canadian Aids Treatment Information Exchange [CATIE]. (2010). *Programming Connection case study: Overdose prevention project, StreetWorks*, Edmonton: CATIE. Retrieved from: <http://www.catie.ca/en/pc/program/overdose-prevention-project>
- Chaparro, L.E., Furlan, A.D., Deshpande, A., Mailis-Gagnon, A., Atlas, S., & Turk, D.C. (2013). Opioids compared to placebo or other treatments for chronic low-back pain. *Cochrane Database Systematic Reviews*, 8, CD004959.
- Chou, R., Ballantyne, J.C., Fanciullo, G.J., Fine, P.G., & Miaskowski, C. (2009). Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. *Journal of Pain, 10*, 147–159.
- Clark, A., Wilder, C.M., & Winstanley, E.L. (2014). A systematic review of community opioid overdose prevention and naloxone distribution programs. *Journal of Addiction Medicine, 8*, 153–163.
- Coffin, P., & Banta-Green, C. (2014). The dueling obligations of opioid stewardship. *Annals of Internal Medicine, 160*, 207–208.
- Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., [...] & Taylor, R.S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. *Health Technology Assessment, 11*(9), 1–171.
- Corrigan, M., Wilson, S.S., & Hampton, J. (2015). Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. *American Journal of Health-System Pharmacy, 72*(18), 1544-1554. doi: 10.2146/ajhp140630
- Cottler, L.B., Compton, W.M., Ben Abdallah, A., Cunningham-Williams, R., Abram, F., Fichtemberg, C., & Dotson, W. (1998). Peer-delivered interventions reduce HIV risk behaviors among out-of-treatment drug abusers. *Public Health Reports, 113*(S1), 31-41.
- Darke, S., Williamson, A., Ross, J., & Teesson, M. (2005). Non-fatal heroin overdose, treatment exposure and client characteristics: Findings from the Australian Treatment Outcome Study (ATOS). *Drug and Alcohol Review 24*, 425–432.
- Darke, S. & Hall, W. (2003). Heroin overdose: Research and evidence-based intervention. *Journal of Urban Health, 80*, 189–200.
- Darke, S., Mills, K.L., Ross, J., & Teesson, M. (2011). Rates and correlates of mortality amongst heroin users: Findings from the Australian Treatment Outcome Study (ATOS), 2001–2009. *Drug and Alcohol Dependence, 115*, 190–195.
- Davidson, P.J., Ochoa, K.C., Hahn, J.A., Evans, J.L., & Moss, A.R. (2002). Witnessing heroin-related overdoses: The experiences of young injectors in San Francisco. *Addiction, 97*, 1511–1516.
- Davis, C., Webb, D., & Burris, S. (2013). Changing law from barrier to facilitator of opioid overdose prevention. *Journal of Law, Medicine & Ethics, Spring*, 33–36.
- Day, C., Conroy, E., Lowe, J., Page, J., & Dolan, K. (2006). Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. *Australian Journal of Rural Health, 14*, 120–125.

- Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2011). Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. *Addiction, 106*, 32–51.
- Degenhardt, L., Larney, S., Kimber, J., Gisev, N., Farrell, M., [...] & Burns, L. (2014). The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study. *Addiction Research Report*. Epub ahead of print doi:10.1111/add.12536
- Dhalla, I., & Laupacis, A. (2008). Moving from opacity to transparency in pharmaceutical policy. *CMAJ, 178*, 428–431.
- Dhalla, I., Persaud, N., & Juurlink, D.N. (2011). Facing up to the prescription opioid crisis. *BMJ, 343*:d5142.
- Dowell, D., Kunins, H.V., & Farley, T.A. (2013). Opioid analgesics—risky drugs, not risky patients. *JAMA, 309*, 2219–2220.
- Dwyer, K., Walley, A.Y., Langlois, B.K., Mitchell, P.M., Nelson, K.P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *Western Journal of Emergency Medicine, 16* (3).
- Eggertson, L. (2013). Take-home naloxone kits preventing overdose deaths. *CMAJ News, 186*, 17. doi:10.1503/cmaj.109-4663
- El-Aneed, A., Alaghebandan, R., Gladney, N., Collins, K., MacDonald, D., & Fischer, B. (2009). Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. *Journal of Substance Use, 14*, 75–83.
- Enteen, L., Bauer, J., McLean, R., Wheeler, E., Hurliaux, Kral, A., & Bamberger, J.D. (2010). Overdose prevention and naloxone prescription for opioid users in San Francisco. *Journal of Urban Health, 87*, 931–941.
- Feldman L., Williams K.S., Coates J., & Knox, M. (2011). Awareness and utilization of a prescription monitoring program among physicians. *Journal of Pain & Palliative Care Pharmacotherapy, 25*, 313–317.
- Fischer, B. & Rehm, J. (2007). Illicit opioid use in the 21st century: Witnessing a paradigm shift? *Addiction, 102*, 499–501.
- Fischer, B., Patra, J., Firestone-Cruz, M., Gittins, J., & Rehm, J. (2008). Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. *Drug & Alcohol Review, 27*, 625–632.
- Fischer, B., Jones, W., & Rehm, J. (2013). High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005 – 2009. *Pharmacoepidemiology and Drug Safety, 22*, 438–442.
- Fudula, P.J., Bridge, P., Herbert, S., Williford, W.O., Chiang, C. N., [...] & Tusel, D. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *New England Journal of Medicine, 349*, 949–958.
- Gibson, A., Degenhardt, L., Mattick, R.P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction, 103*, 462–468.
- Goldacre, B., Carroll, D., & Hall, E. (2013). Guidelines for collaboration with industry should be transparent. *BMJ, 347*, f6100.
- Green, T.C., Heimer, R., & Grau, L.E. (2008). Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. *Addiction, 103*(6), 979-989. doi:10.1111/j.1360-0443.2008.02182.x

Overdose Prevention Programming:
Education and Naloxone Distribution

- Grund, J.P., Blanken, P., Adriaans, N.F., Kaplan, C.D., Barendregt, C., & Meeuwse, M. (1992). Reaching the unreached: targeting hidden IDU populations with clean needles via known user groups. *Journal of Psychoactive Drugs*, 24, 41–47.
- Gustafson, D.L., Goodyear, L., & Keough, F. (2008). When the dragon's awake: A needs assessment of people injecting drugs in a small urban centre. *International Journal of Drug Policy*, 19, 189–194.
- Havinga, P., van der Velden, C., de Gee, A., & van der Poel, A. (2014). Differences in sociodemographic, drug use and health characteristics between never, former and current injecting, problematic hard-drug users in the Netherlands. *Harm Reduction Journal*, 11, 6.
- Hayashi, K., Wood, E., Wiebe, L., Qi, J., & Kerr, T. (2010). An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. *International Journal of Drug Policy*, 21, 418–421.
- Hedrich, D., Kerr, T., & Dubois-Arber, F. (2010). Drug consumption facilities in Europe and beyond. In T. Rhodes & D. Hedrich (Eds.), *Harm reduction: Evidence, impacts and challenges*, (pp. 305-331). EMCDDA Monograph, Luxembourg: Publications Office of the European Union.
- Hulse, G.K., Tait, R.J., Comer, S.D., Sullivan, M.A., Jacobs, I.G., & Arnold-Reed, D. (2005). Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. *Drug and Alcohol Dependence*, 79, 351–357.
- International Narcotics Control Board. (2013). Report 2013. Vienna: United Nations. Retrieved from: https://www.incb.org/documents/Publications/AnnualReports/AR2013/English/AR_2013_E.pdf
- Islam, M.M. & Conigrave, K.M. (2007). Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): A review. *Harm Reduction Journal*, 4, 14.
- Jovey R.D., Ennis, J., Gardner-Nix, J., Goldman, B., Hays, H., Lynch M., & Moulin, D. (2003). Use of opioid analgesics for the treatment of chronic noncancer pain — A consensus statement and guidelines from the Canadian Pain Society, 2002. *Pain Research & Management*, 8, 3A–28A.
- Kahan, M., Wilson, L., Mailis-Gagnon, A., & Srivastava, A. (2011). Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: Special populations. *Canadian Family Physician*, 57, 1269–1276.
- Kakko, J., Svanbord, K.D., Kreek, M.J., & Hellig, M. (2003). 1-year retention and social function after buprenorphine assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. *Lancet*, 361, 662–668.
- Kerr, D., Dietze, P., Kelly, A-M., & Jolley, D. (2008). Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration. *Journal of Urban Health*, 85(3), 352-360.
- Kerr, T., Oleson, M., Tyndall, M.W., Montaner, J., & Wood, E. (2005). A description of a peer-run supervised injection site for injection drug users. *Journal of Urban Health*, 82, 267–275. doi:10.1093/jurban/jti050
- Kerr, T., Douglas, D., Peeace, W., Pierre, A., & Wood, E. (2001). *Responding to an emergency: Education, advocacy, and community care by a peer-driven organization of drug users: A case study of the Vancouver Area Network of Drug Users (VANDU)*. Ottawa: Health Canada Hepatitis C Prevention, Support, and Research Program. Retrieved from: <http://pubs.cpha.ca/PDF/P1/20166.pdf>
- Kim, D., Irwin, K.S., & Khoshnood, K. (2009). Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. *American Journal of Public Health*, 99, 402–407.

- Kimber J., Copeland, L., Hickman, M., Macleod, J., McKenzie, J., De Angelis, D., Robertson, J.R. (2010). Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment. *BMJ*, *341*, c3172.
- Kinner, S.A., Milloy, M.J., Wood, E., Qi, J., Zhang, R., & Kerr, T. (2012). Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users. *Addictive Behaviour*, *37*, 691–696.
- Kissin, I. (2013). Long-term opioid treatment of chronic nonmalignant pain: Unproven efficacy and neglected safety? *Journal of Pain Research*, *6*, 513–529.
- Klein, A. (2007). *Sticking points: Barriers to access to needle and syringe programs in Canada*. Toronto: Canadian HIV/AIDS Legal Network. Retrieved from: <http://librarypdf.catie.ca/PDF/P48/stickingpoints.pdf>
- Krebs, E.E., Ramsey, D.C., Milosshoff, J.M., & Bair, M.J. (2011). Primary care monitoring of long-term opioid therapy among veterans with chronic pain. *Pain Medicine*, *12*, 740–746.
- Kroenke, K., Krebs, E.E., Wu, J., Yu, Z., Chumbler, N.R., & Bair, M.J. (2014). Telecare collaborative management of chronic pain in primary care: A randomized clinical trial. *JAMA*, *312*, 240–248.
- Leece, P.N., Hopkins, S., Marshall, C., Orkin, A., Gassanov, M.A., & Shahin, R.M. (2013). Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. *Canadian Journal of Public Health*, *104*, e200–e204.
- Luty, J., O’Gara, C., & Sessay, M. (2005). Is methadone too dangerous for opiate addiction? *BMJ*, *331*, 1352–1353.
- Marshall, B.D., Milloy, M.J., Wood, E., Montaner, J.S., & Kerr, T. (2011). Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: A retrospective population-based study. *Lancet*, *377*, 1429–1437.
- Maxwell, S., Bigg, D., Stanczykiewicz, K., & Carlberg-Racich, S. (2006). Prescribing naloxone to actively injecting heroin users: A program to reduce heroin overdose deaths. *Journal of Addictive Diseases*, *25*, 89–96.
- McCutcheon, J.M. & Morrison, M.A. (2014). Injecting on the Island: A qualitative exploration of the service needs of persons who inject drugs in Prince Edward Island. *Canada Harm Reduction Journal*, *11*, 10.
- McDermott, C. & Collins, N.C. (2012). Prehospital medication administration: a randomised study comparing intranasal and intravenous routes. *Emergency Medicine International*, *2012*(2012).
- Mello, M.M., Wood, J., Burris, S., Wagenaar, A.C., Ibrahim, J.K., & Swanson, J.W. (2013). Critical opportunities for public health law: A call for action. *American Journal of Public Health*, *103*, 1979–1988.
- Milloy, M.J., Kerr, T., Mathias, R., Zhang, R., Montaner, J.S., Tyndall, M., & Wood, E. (2008). Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. *American Journal of Drug & Alcohol Abuse*, *34*, 499–509.
- Moore, D. (2004). Governing street-based injecting drug users: A critique of heroin overdose prevention in Australia. *Social Science & Medicine*, *59*, 1547–1557.
- Noble, M., Tregear, S.J., Treadwell, J.R., & Schoelles, K. (2008). Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. *Journal of Pain Symptom Management*, *35*, 214–228.
- Nüesch, E., Rutjes, A.W., Husni, E., Welch, V., & Jüni, P. (2009). Oral or transdermal opioids for osteoarthritis of the knee or hip. *Cochrane Database Systematic Reviews*, *4*, CD003115.

Overdose Prevention Programming:
Education and Naloxone Distribution

- Orkin, A.M., Bingham, K., Klaiman, M., Leece, P., Buick, J.E., [...] & Hu, H. (2015). An agenda for naloxone distribution research and practice: Meeting report of the surviving opioid overdose with naloxone (SOON) International Working Group. *Journal of Addiction Research & Therapy*, 6(1). doi:10.4172/2155-6105.1000212
- Parker, J., Jackson, L., Dykeman, M., Gahagan, J., & Karabanow, J. (2012). Access to harm reduction services in Atlantic Canada: Implications for non-urban residents who inject drugs. *Health & Place*, 18, 152–162.
- Persaud, N. (2013). Questionable content of an industry-supported medical school lecture series: A case study. *Journal of Medical Ethics*. doi:10.1136/medethics-2013-101343.
- Piper, T.M., Stancliff, S., Rudenstine, S., Sherman, S., Nandi, V., Clear, A., & Galea, S. (2008). Evaluation of a naloxone distribution and administration program in New York City. *Substance Use & Misuse*, 43, 858-870. doi: 10.1080/10826080701801261.
- Popova, S., Patra, J., Mohapatra, S., Fischer, B., & Rehm, J. (2009). How many people in Canada use prescription opioids non-medically in general and street drug using populations? *Canadian Journal of Public Health*, 100, 104–108.
- Poschade, S., Hoyer, R., & Schnitzler, J. (2003). Evaluation der Arbeit der Drogenkonsumräume in der Bundesrepublik Deutschland. Endbericht im Auftrag des Bundesministeriums für Gesundheit. Baden-Baden: Nomos.
- Rhodes, T. (2002). The 'risk environment': A framework for understanding and reducing drug-related harm. *International Journal of Drug Policy*, 13, 85–94.
- Rich, J.D., Wolf, F.A., & Macalino, G. (2002). Strategies to improve access to sterile syringes for injection drug users. *The AIDS Reader*, 12, 527–535.
- Robertson, T.M., Hendey, G.W., Stroh, G., & Shalit, M. (2009). Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. *Prehospital Emergency Care*, 13, 512–515.
- Robinson, A. & Wermeling, D. P. (2014). Intranasal naloxone administration for treatment of opioid overdose. *American Journal of Health-System Pharmacy*, 71(24), 2129-2135. doi : 10.2146/ajhp130798
- Simeone, R., & Holland, L. (2006). *An evaluation of prescription drug monitoring programs*. Washington, DC: US Department of Justice, Office of Justice Programs. Retrieved from: <http://www.simeoneassociates.com/simeone3.pdf>
- Small, W., Wood, E., Tobin, D., Rikley, J., Lapushinsky, D., & Kerr, T. (2012). The injection support team: A peer-driven program to address unsafe injecting in a Canadian setting. *Substance Use & Misuse*, 47, 491–501.
- Snead, J., Downing, M., Lorvick, J., Garcia, B., Thawley, R., Kegeles, S., & Edlin, B.R. (2003). Syringe exchange among injection drug users. *Journal of Urban Health*, 80, 330–348.
- Soyka, M., Apelt, S.M., Lieb, M., & Wittchen, H.U. (2006). One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: A nationally representative cohort study in 2694 patients. *Journal of Clinical Psychopharmacology*, 26, 657–660.
- Spielmans, G.I., & Parry, P.I. (2010). From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. *Bioethical Inquiry*, 7, 13–29.
- Strang, J., Babor, T., Caulkins, J., Fischer, B., Foxcroft, D., & Humphreys, K. (2012). Drug policy and the public good: evidence for effective interventions. *Lancet*, 379, 71–83.

- Straus, M.M., Ghitza, U.E., & Tai, B. (2013). Preventing deaths from rising opioid overdose in the US – The promise of naloxone antidote in community-based naloxone take-home programs. *Substance Abuse and Rehabilitation, 4*, 65–72.
- Tobin, K.E., Davey, M.A., & Latkin, C.A. (2005). Calling emergency medical services during drug overdose: An examination of individual, social and setting correlates. *Addiction, 100*, 397–404.
- Umbricht, A., Huestis, M. A., Cone, E. J., & Preston, K. L. (2004). Effects of high-dose intravenous buprenorphine in experienced opioid abusers. *Journal of Clinical Psychopharmacology, 24*, 479–487.
- United Nations Commission on Narcotic Drugs. (2012). *Resolution 55/7: promoting measures to prevent drug overdose, in particular opioid overdose*. Vienna: United Nations Economic and Social Council.
- Van Zee, A. (2009). The promotion and marketing of oxycontin: commercial triumph, public health tragedy. *American Journal of Public Health, 99*, 221–227.
- Wagner, K.D., Davidson, P.J., Iverson, E., Washburn, R., Burke, E., [...] & Lankenau, S.E. (2014). “I felt like a superhero”: The experience of responding to drug overdose among individuals trained in overdose prevention. *International Journal of Drug Policy, 25*, 157–165.
- Walley, A.Y., Xuan, Z., Hackman, H.H., Quinn, E., Doe-Simkins, M., [...] & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. *BMJ, 346*, f174.
- Wardman, D. & Quantz, D. (2006) Harm reduction services for British Columbia’s First Nation population: A qualitative inquiry into opportunities and barriers for injection drug users. *Harm Reduction Journal, 3*, 30.
- Wheeler, E., Davidson, P.J., Jones, S., & Irwin, K.S. (2012). Community-based opioid overdose prevention programs providing naloxone — United States, 2010. *Morbidity and Mortality Weekly Report, 61*, 101–105.
- Wood, E., Kerr, T., Spittal, P.M., Small, W., Tyndall, M.W., O’Shaughnessy, M.V., & Schechter, M.T. (2003). An external evaluation of a peer-run “unsanctioned” syringe exchange program. *Journal of Urban Health, 80*, 455-464.

March 2016

Author: Valerie Webber, National Collaborating Centre for Healthy Public Policy

With the collaboration of: François Gagnon, National Collaborating Centre for Healthy Public Policy

Editing: Michael Keeling and Marianne Jacques, National Collaborating Centre for Healthy Public Policy

SUGGESTED CITATION

Webber, V. (2016). *Overdose Prevention Programming: Education and Naloxone Distribution. Practical Guide*. Montréal, Québec: National Collaborating Centre for Healthy Public Policy.

ACKNOWLEDGMENTS

The NCCHPP would like to thank Dr. Lori Kiefer, Ministry of Community Safety and Correctional Services of Ontario, Ashraf Amlani, British Columbia Centre for Disease Control, Dr. Jane Buxton, British Columbia Centre for Disease Control, Dr. Marie-Ève Goyer, Centre de recherche et d'aide pour narcomanes, Nicolas Hamel, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'île-de-Montréal, as well as a group of anonymous reviewers for their thoughtful comments on an earlier version of this document.

The National Collaborating Centre for Healthy Public Policy (NCCHPP) seeks to increase the expertise of public health actors across Canada in healthy public policy through the development, sharing and use of knowledge. The NCCHPP is one of six centres financed by the Public Health Agency of Canada. The six centres form a network across Canada, each hosted by a different institution and each focusing on a specific topic linked to public health. In addition to the Centres' individual contributions, the network of Collaborating Centres provides focal points for the exchange and common production of knowledge relating to these topics. The National Collaborating Centre for Healthy Public Policy is hosted by the Institut national de santé publique du Québec (INSPQ), a leading centre in public health in Canada.

Production of this document has been made possible through a financial contribution from the Public Health Agency of Canada through funding for the National Collaborating Centre for Healthy Public Policy (NCCHPP). The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.

All images in this document have been reproduced with permission or in accordance with licences authorizing their reproduction. Should you discover any errors or omissions, please advise us at ncchpp@inspq.qc.ca.

Publication N°: XXXX

This document is available in its entirety in electronic format (PDF) on the National Collaborating Centre for Healthy Public Policy website at: www.ncchpp.ca/.

La version française est disponible sur le site Web du Centre de collaboration nationale sur les politiques publiques et la santé au : www.ccnpps.ca.

Information contained in the document may be cited provided that the source is mentioned.

